United Biosource Corporation

学者数642

论文数623

被引数0

关联论文 (623)

发表时间

Five years of post-marketing liver safety data from the tolvaptan Risk Evaluation and Mitigation Strategy

CLINICAL KIDNEY JOURNAL

IF4.6

2025-02-25

OAAI

Lohrmann, Emanuel; Jaeger, Thomas; Enekebe, Kene; Zhang, Zhen; Wilt, Timothy; Riggen, Michele; Stemhagen, Annette; Nair, Indu; Nunna, Sasikiran; Fernandes, Ancilla W.; Gandhi, Hema; Sergeyeva, Olga; George, Vinu

Single-egg comet assay: A protocol to quantify DNA damage in natural bioarchives

METHODS IN ECOLOGY AND EVOLUTION

IF6.2

2025-01-15

OAAI

Salimraj, Rejin; Perotti, Alessio; Wojewodzic, Marcin W.; Frisch, Dagmar

Safety Surveillance During Drug Development: Comparative Evaluation of Existing Regulations

ADVANCES IN THERAPY

IF4

2023-04-05

OAAI

Samara, Chrysanthi; Garcia, Alix; Henry, Christopher; Vallotton, Laure; Cariolato, Luca; Desmeules, Jules; Pincon, Alexis

Evaluating the Impact of a Risk Evaluation and Mitigation Strategy With Tolvaptan to Monitor Liver Safety in Patients with Autosomal Dominant Polycystic Kidney Disease

CLINICAL KIDNEY JOURNAL

IF4.6

2022-03-11

OAAI

Estilo, Alvin; Tracy, LaRee; Matthews, Carol; Riggen, Michele; Stemhagen, Annette; Wilt, Timothy; Krakovich, Anatoliy; Jones-Burton, Charlotte; George, Vinu; McQuade, Robert; Rahman, Mirza

Machine learning for comprehensive forecasting of Alzheimer's Disease progression

SCIENTIFIC REPORTS

IF3.9

2019-09-20

118

OAAI

Fisher, Charles K.; Smith, Aaron M.; Walsh, Jonathan R.; Simone, Adam J.; Edgar, Chris; Jack, Clifford R.; Holtzman, David; Russell, David; Hill, Derek; Grosset, Donald; Wood, Fred; Vanderstichele, Hugo; Morris, John; Blennown, Kaj; Marek, Ken; Shaw, Leslie M.; Albert, Marilyn; Weiner, Michael; Fox, Nick; Aisen, Paul; Cole, Patricia E.; Petersen, Ronald; Sherer, Todd; Kubick, Wayne

The Impact of Malaria on Liver Enzymes: A Retrospective Cohort Study (2010-2017)

OPEN FORUM INFECTIOUS DISEASES

IF3.8

2019-05-16

OAAI

Cheaveau, James; Marasinghe, Dewdunee; Akakpo, Samantha; Deardon, Rob; Naugler, Christopher; Chin, Alex; Pillai, Dylan R.

A prospective observational safety study of patients with BRAFV600-mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study)

BRITISH JOURNAL OF DERMATOLOGY

IF9.6

2019-02-10

PREAI

Corrie, P. G.; Terheyden, P.; ten Tije, A. J.; Herbst, R.; Jansen, R.; Marples, M.; Debus, D.; Marconcini, R.; Blasinska-Morawiec, M.; Freivogel, K.; Munson, M. L. G.; Goodman, G. R.; Hsu, J. J.; Sadetsky, N.; Colburn, D.; Rutkowski, P.

Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada Comparative efficacy and cost-effectiveness

THROMBOSIS AND HAEMOSTASIS

IF4.3

2017-11-29

PREAI

Kansal, Anuraag R.; Sharma, Michael; Bradley-Kennedy, Carole; Clemens, Andreas; Monz, Brigitta U.; Peng, Siyang; Roskell, Neil; Sorensen, Sonja V.

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective

THROMBOSIS AND HAEMOSTASIS

IF4.3

2017-11-28

160

PREAI

Sorensen, Sonja V.; Kansal, Anuraag R.; Connolly, Stuart; Peng, Siyang; Linnehan, John; Bradley-Kennedy, Carole; Plumb, Jonathan M.

A threshold method for immunological correlates of protection (vol 13, 29, 2013)

BMC MEDICAL RESEARCH METHODOLOGY

IF3.4

2017-02-02

OAAI

Chen, Xuan; Bailleux, Fabrice; Desai, Kamal; Qin, Li; Dunning, Andrew J.

QUETIAPINE OFF-LABEL USE

VALUE IN HEALTH

IF6

2016-11-01

OAAI

Levin, R.; Cosmatos, I; Dieck, G.; Reifsnyder, J.

Comparative Analysis of Length of Stay and Inpatient Costs for Orthopedic Surgery Patients Treated with IV Acetaminophen and IV Opioids vs. IV Opioids Alone for Post-Operative Pain (vol 33, pg 1635, 2016)

ADVANCES IN THERAPY

IF4

2016-08-25

OAAI

Hansen, Ryan N.; An Pham; Strassels, Scott A.; Balaban, Stela; Wan, George J.

Comparative Analysis of Length of Stay and Inpatient Costs for Orthopedic Surgery Patients Treated with IV Acetaminophen and IV Opioids vs. IV Opioids Alone for Post-Operative Pain

ADVANCES IN THERAPY

IF4

2016-07-16

OAAI

Hansen, Ryan N.; An Pham; Strassels, Scott A.; Balaban, Stela; Wan, George J.

USE OF DATABASES FOR HEALTH RESOURCE UTILIZATON AND COST ANALYSES IN EU-5: RESULTS FROM A FOCUSED LITERATURE REVIEW

VALUE IN HEALTH

IF6

2016-05-01

OAAI

De Cock, E.; Cosmatos, I; Kirsch, E.

COMBINING MULTIPLE DATA SOURCES IN A SINGLE STUDY: STRENGTHS OF HYBRID STUDY METHODOLOGY

VALUE IN HEALTH

IF6

2016-05-01

OAAI

Kritikou, P.; Stein, D.; De Cock, E.; Hanson, K. A.

A RISK ANALYSIS MODEL TO EVALUATE SAFE DELIVERY AND USE OF THE FIRST CHEMOTHERAPY INJECTION FOR HOME ADMINISTRATION: OMACETAXINE MEPESUCCINATE

VALUE IN HEALTH

IF6

2016-05-01

OAAI

Kim, S.; Stemhagen, A.; Barrale, R.; Hood, Van Wart J.; Pathak, A.

TRACKING ANTIPSYCHOTIC POLYPHARMACY AND TREATMENT PATTERNS

VALUE IN HEALTH

IF6

2016-05-01

OAAI

Levin, R.; Cosmatos, I; Germsheid, L.

OBSERVATIONAL STUDIES EVALUATING BIOSIMILAR AGENTS: A FOCUSED LITERATURE REVIEW

VALUE IN HEALTH

IF6

2016-05-01

OAAI

Mokiou, S.; De Cock, E.

INCREASING PRECISION OF REAL-WORLD DATA ESTIMATES: THE IMPORTANCE OF A STEP-WISE PROCESS TO LIMIT DATA COLLECTION ERRORS AND DATA INCOMPLETENESS

VALUE IN HEALTH

IF6

2015-11-01

OAAI

Kritikon, P.; de Cock, E.; Stein, D.

RESULTS FROM A TIME AND MOTION STUDY OF DENOSUMAB SUBCUTANEOUS INJECTION AND ZOLEDRONIC ACID INTRAVENOUS INFUSION IN PATIENTS WITH METASTATIC BONE DISEASE FROM ITALIAN SITES

VALUE IN HEALTH

IF6

2015-11-01

OAAI

Pedrazzoli, P.; Caraceni, A.; Beano, A.; Adamo, V; Testore, F.; Pigni, A.; Body, J.; Sgreccia, L.; de Cock, E.; Tao, S.; Kritikou, P.; Hechmati, G.; Gatta, F.